Reported Earnings • Apr 29
Full year 2025 earnings released: EPS: CN¥0.43 (vs CN¥0.34 in FY 2024) Full year 2025 results: EPS: CN¥0.43 (up from CN¥0.34 in FY 2024). Revenue: CN¥219.7m (up 8.0% from FY 2024). Net income: CN¥28.9m (up 26% from FY 2024). Profit margin: 13% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Apr 29
AVE Science&Technology CO.,LTD, Annual General Meeting, May 22, 2026 AVE Science&Technology CO.,LTD, Annual General Meeting, May 22, 2026, at 14:30 China Standard Time. Location: No. 26, Fuling Road, Xueshi Subdistrict, Yuelu District, Changsha, Hunan China Announcement • Mar 30
AVE Science&Technology CO.,LTD to Report Q1, 2026 Results on Apr 29, 2026 AVE Science&Technology CO.,LTD announced that they will report Q1, 2026 results on Apr 29, 2026 Reported Earnings • Mar 01
Full year 2025 earnings released: EPS: CN¥0.43 (vs CN¥0.34 in FY 2024) Full year 2025 results: EPS: CN¥0.43 (up from CN¥0.34 in FY 2024). Revenue: CN¥230.0m (up 13% from FY 2024). Net income: CN¥28.9m (up 27% from FY 2024). Profit margin: 13% (up from 11% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Announcement • Dec 26
AVE Science&Technology CO.,LTD to Report Fiscal Year 2025 Results on Apr 29, 2026 AVE Science&Technology CO.,LTD announced that they will report fiscal year 2025 results on Apr 29, 2026 Board Change • Dec 12
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Ping Wan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Dec 11
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.22 (vs CN¥0.20 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.22 (up from CN¥0.20 in 3Q 2024). Revenue: CN¥61.4m (up 9.8% from 3Q 2024). Net income: CN¥15.2m (up 12% from 3Q 2024). Profit margin: 25% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 10% per year. Announcement • Sep 30
AVE Science&Technology CO.,LTD to Report Q3, 2025 Results on Oct 30, 2025 AVE Science&Technology CO.,LTD announced that they will report Q3, 2025 results on Oct 30, 2025 Announcement • Jun 30
AVE Science&Technology CO.,LTD to Report First Half, 2025 Results on Aug 29, 2025 AVE Science&Technology CO.,LTD announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • Apr 29
AVE Science&Technology CO.,LTD, Annual General Meeting, May 23, 2025 AVE Science&Technology CO.,LTD, Annual General Meeting, May 23, 2025, at 14:30 China Standard Time. Announcement • Mar 28
AVE Science&Technology CO.,LTD to Report Q1, 2025 Results on Apr 29, 2025 AVE Science&Technology CO.,LTD announced that they will report Q1, 2025 results on Apr 29, 2025 Reported Earnings • Mar 02
Full year 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.32 in FY 2023) Full year 2024 results: EPS: CN¥0.34 (up from CN¥0.32 in FY 2023). Revenue: CN¥204.6m (up 2.2% from FY 2023). Net income: CN¥23.0m (up 6.7% from FY 2023). Profit margin: 11% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 12% per year. Announcement • Dec 27
AVE Science&Technology CO.,LTD to Report Fiscal Year 2024 Results on Apr 29, 2025 AVE Science&Technology CO.,LTD announced that they will report fiscal year 2024 results on Apr 29, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.20 (down from CN¥0.20 in 3Q 2023). Revenue: CN¥55.9m (flat on 3Q 2023). Net income: CN¥13.5m (down 8.4% from 3Q 2023). Profit margin: 24% (down from 26% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
AVE Science&Technology CO.,LTD to Report Q3, 2024 Results on Oct 30, 2024 AVE Science&Technology CO.,LTD announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to CN¥16.28, the stock trades at a trailing P/E ratio of 46.5x. Average trailing P/E is 31x in the Medical Equipment industry in China. Total loss to shareholders of 40% over the past three years. New Risk • Sep 10
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. Reported Earnings • Sep 03
Second quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.12 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.12 in 2Q 2023). Revenue: CN¥50.4m (down 6.4% from 2Q 2023). Net income: CN¥6.53m (down 9.3% from 2Q 2023). Profit margin: 13% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Announcement • Jul 06
AVE Science&Technology CO.,LTD (SHSE:688067) announces an Equity Buyback for CNY 20 million worth of its shares. AVE Science&Technology CO.,LTD (SHSE:688067) announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at no more than CNY 21.8 per share. The purpose of the program is to reduce share capital, to use the repurchased shares for employee stock ownership plan or equity incentives, to convert company convertible bonds and to maintain company value and shareholders' rights. If the company fails to use up all the repurchased shares within 3 years after the announcement of the results of the share repurchase and the share changes, the unused repurchased shares will be cancelled. The program will be funded from company's own funds. The plan will be valid for 6 months. Announcement • Jun 29
AVE Science&Technology CO.,LTD to Report First Half, 2024 Results on Aug 29, 2024 AVE Science&Technology CO.,LTD announced that they will report first half, 2024 results on Aug 29, 2024 New Risk • May 14
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Large one-off items impacting financial results. Announcement • Apr 29
AVE Science&Technology CO.,LTD, Annual General Meeting, May 24, 2024 AVE Science&Technology CO.,LTD, Annual General Meeting, May 24, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Changsha, Hunan China Reported Earnings • Apr 27
Full year 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.26 in FY 2022) Full year 2023 results: EPS: CN¥0.32 (up from CN¥0.26 in FY 2022). Revenue: CN¥200.3m (up 1.8% from FY 2022). Net income: CN¥21.5m (up 20% from FY 2022). Profit margin: 11% (up from 9.1% in FY 2022). Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥13.58, the stock trades at a trailing P/E ratio of 42.4x. Average trailing P/E is 28x in the Medical Equipment industry in China. Total loss to shareholders of 38% over the past year. Announcement • Mar 30
AVE Science&Technology CO.,LTD to Report Q1, 2024 Results on Apr 27, 2024 AVE Science&Technology CO.,LTD announced that they will report Q1, 2024 results on Apr 27, 2024 Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥19.45, the stock trades at a trailing P/E ratio of 60.7x. Average trailing P/E is 30x in the Medical Equipment industry in China. Total loss to shareholders of 9.3% over the past year. Reported Earnings • Feb 28
Full year 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.26 in FY 2022) Full year 2023 results: EPS: CN¥0.32 (up from CN¥0.26 in FY 2022). Revenue: CN¥200.5m (up 1.9% from FY 2022). Net income: CN¥21.8m (up 21% from FY 2022). Profit margin: 11% (up from 9.1% in FY 2022). Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment deteriorates as stock falls 31% After last week's 31% share price decline to CN¥12.78, the stock trades at a trailing P/E ratio of 47.7x. Average trailing P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 38% over the past year. New Risk • Feb 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (120% cash payout ratio). Share price has been volatile over the past 3 months (7.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.2% net profit margin). Valuation Update With 7 Day Price Move • Jan 23
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥19.05, the stock trades at a trailing P/E ratio of 71.1x. Average trailing P/E is 30x in the Medical Equipment industry in China. Total loss to shareholders of 3.7% over the past year. Announcement • Dec 30
AVE Science&Technology CO.,LTD to Report Fiscal Year 2023 Results on Apr 27, 2024 AVE Science&Technology CO.,LTD announced that they will report fiscal year 2023 results on Apr 27, 2024 Reported Earnings • Oct 29
Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.17 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.20 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥56.1m (down 1.6% from 3Q 2022). Net income: CN¥14.8m (up 24% from 3Q 2022). Profit margin: 26% (up from 21% in 3Q 2022). Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.09 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.12 (up from CN¥0.09 in 2Q 2022). Revenue: CN¥53.8m (up 14% from 2Q 2022). Net income: CN¥7.20m (up 18% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Announcement • Jun 28
AVE Science&Technology CO.,LTD to Report First Half, 2023 Results on Aug 30, 2023 AVE Science&Technology CO.,LTD announced that they will report first half, 2023 results on Aug 30, 2023 Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.09 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.03 (down from CN¥0.09 in 1Q 2022). Revenue: CN¥40.9m (down 11% from 1Q 2022). Net income: CN¥2.15m (down 63% from 1Q 2022). Profit margin: 5.2% (down from 13% in 1Q 2022). The decrease in margin was driven by lower revenue. Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.53 in FY 2021) Full year 2022 results: EPS: CN¥0.26 (down from CN¥0.53 in FY 2021). Revenue: CN¥196.8m (down 6.6% from FY 2021). Net income: CN¥18.0m (down 43% from FY 2021). Profit margin: 9.1% (down from 15% in FY 2021). Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Qiulin Yang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 29
Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.21 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.17 (down from CN¥0.21 in 3Q 2021). Revenue: CN¥57.0m (up 3.1% from 3Q 2021). Net income: CN¥11.9m (down 20% from 3Q 2021). Profit margin: 21% (down from 27% in 3Q 2021). Reported Earnings • Aug 31
Second quarter 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.12 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.09. Revenue: CN¥47.4m (down 5.3% from 2Q 2021). Net income: CN¥6.11m (up 1.1% from 2Q 2021). Profit margin: 13% (in line with 2Q 2021). Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥23.70, the stock trades at a trailing P/E ratio of 52.8x. Average trailing P/E is 30x in the Medical Equipment industry in China. Reported Earnings • Apr 28
First quarter 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.13 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.09 (down from CN¥0.13 in 1Q 2021). Revenue: CN¥46.1m (down 2.5% from 1Q 2021). Net income: CN¥5.84m (down 11% from 1Q 2021). Profit margin: 13% (down from 14% in 1Q 2021). The decrease in margin was driven by lower revenue. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Feb 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CN¥0.53 (down from CN¥0.59 in FY 2020). Revenue: CN¥210.8m (up 17% from FY 2020). Net income: CN¥31.4m (up 4.2% from FY 2020). Profit margin: 15% (down from 17% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Reported Earnings • Nov 01
Third quarter 2021 earnings released The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥55.3m (up 20% from 3Q 2020). Net income: CN¥14.9m (down 4.0% from 3Q 2020). Profit margin: 27% (down from 34% in 3Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥50.1m (up 22% from 2Q 2020). Net income: CN¥6.04m (down 11% from 2Q 2020). Profit margin: 12% (down from 17% in 2Q 2020). The decrease in margin was driven by higher expenses.